Patents Examined by Kimberly Chong
  • Patent number: 10640768
    Abstract: The present invention provides a screening method for pain suppressors, which method is characterized by using netrin-4 and/or a netrin-4 receptor to select a substance capable of inhibiting downstream signaling from netrin-4. According to the screening method of the present invention, pain suppressors useful as a preventive or therapeutic medicine for pain can be identified. The present invention also provides a pharmaceutical composition for prevention or treatment of pain, which composition comprises, as an active ingredient, a substance capable of inhibiting downstream signaling from netrin-4.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: May 5, 2020
    Assignee: OSAKA UNIVERSITY
    Inventors: Toshihide Yamashita, Yasufumi Hayano
  • Patent number: 10633655
    Abstract: The present invention features compositions and methods relating to tRNA-derived small RNAs (tsRNAs). Provided herein are oligonucleotide compositions that are complementary to tsRNAs, in particular leuCAGtsRNA, and methods of using the oligonucleotides for the regulation of respective tsRNA. Further provided are methods of inducing apoptosis through the inhibition of leuCAGtsRNA.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: April 28, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mark A. Kay, Hak Kyun Kim, Shengchun Wang
  • Patent number: 10633660
    Abstract: The invention relates to antisense oligonucleotidic sequences (ODN) against Smad7 suitably modified, and their uses in medical field as therapeutic biological agents, in particular in the treatment of chronic inflammatory bowel disease, such as Crohn's disease and ulcerative colitis.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: April 28, 2020
    Assignee: Nogra Pharma Limited
    Inventor: Giovanni Monteleone
  • Patent number: 10632140
    Abstract: The methods and assays described herein relate to detection, diagnosis, and treatment of lung cancer, e.g., by detecting the level of expression of certain miRNAs described herein and/or by therapeutically increasing the level of those miRNAs.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: April 28, 2020
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Ana Brandusa Pavel, Joshua David Campbell, Marc Elliott Lenburg, Avrum Elliot Spira
  • Patent number: 10626401
    Abstract: The invention relates to non-CpG single-stranded oligonucleotides (ssONs) for use in the treatment or prophylaxis of disorders of the skin and/or subcutaneous tissue, including pruritus, in a suitable formulation or in combination with other immunomodulatory treatments. The said ssONs have a length of at least 25 nucleotides and are stabilized by phosphorothioate internucleotide linkages and/or 2?-O-Methyl modifications.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: April 21, 2020
    Assignee: TIRMED PHARMA AB
    Inventors: Anna-Lena Spetz, Peter Jarver, Annette Skold
  • Patent number: 10619158
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: April 14, 2020
    Assignee: IONIS Pharmaceuticals, Inc.
    Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
  • Patent number: 10619157
    Abstract: In certain embodiments, methods, compounds, and compositions for treating B-cell lymphoma or hepatocellular carcinoma by inhibiting expression of STAT3 mRNA or protein in an animal are provided herein. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate B-cell lymphoma or hepatocellular carcinoma.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: April 14, 2020
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Stanley T. Crooke, Mason Yamashita
  • Patent number: 10610574
    Abstract: Methods of treating an age-related disorder in a subject are provided. Aspects of the methods include administering to the subject a nucleic acid vector including a coding sequence for telomerase reverse transcriptase (TERT) and/or telomerase RNA (TR). Gene therapy methods are also provided. Aspects of the invention further include compositions, e.g., nucleic acid vectors and kits, etc., that find use in methods of the invention.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: April 7, 2020
    Assignee: Sierra Sciences, LLC
    Inventors: William H. Andrews, Lancer K. Brown, Hamid Mohammadpour, Laura A. Briggs
  • Patent number: 10591489
    Abstract: Chronic inflammation is an increasing medical problem area of high socioeconomic significance. The invention relates to a method and a kit for diagnosing a molecular phenotype of a patient suffering from an illness accompanied by chronic inflammation, and to a medicament for treating such a patient. To that end, the gene expression of GATA-3 and/or Tbet in a biological isolate of the patient is measured and used for association with a molecular phenotype of the illness.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: March 17, 2020
    Assignee: STERNA BIOLOGICALS GMBH & CO. KG
    Inventors: Agnieszka Turowska, Joachim Bille
  • Patent number: 10584144
    Abstract: The presently-disclosed subject matter relates to an artificial RNA nanostructure molecule and method to treat brain tumor in a subject. More particularly, the presently disclosed subject matter relates to a RNA nanostructure containing a multiple branched RNA nanoparticle, a brain tumor targeting module, and an effective amount of a therapeutic agent. Further, the presently disclosed subject matter relates to a method of using the RNA nanostructure composition to treat brain tumor in a subject having or at risk of having brain tumor.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: March 10, 2020
    Assignee: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
    Inventors: Peixuan Guo, Carlo M. Croce, Tae Jin Lee, Farzin Haque, Hui Li
  • Patent number: 10577605
    Abstract: The invention relates to the use of an antisense compound for inducing exon inclusion as a treatment for Spinal Muscle Atrophy (SMA). More particularly it relates to inducing inclusion of exon 7 to restore levels of Survival Motor Neuron (SMN) protein encoded by the Survival Motor Neuron (SMN) gene.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: March 3, 2020
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Peter Linsley, Brian James Leppert
  • Patent number: 10570396
    Abstract: Cell death is induced and/or cell growth is suppressed for a cell having a mutation in the BRAF gene. A drug suppressing GST-? is comprised as an active ingredient.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: February 25, 2020
    Assignee: Nitto Denko Corporation
    Inventors: Yoshiro Niitsu, Hiroki Nishita
  • Patent number: 10548990
    Abstract: Double-stranded modified siRNA targeting a RecQL1 helicase gene includes a sense strand including the nucleotide sequence shown in SEQ ID NO: 1, and an antisense strand including the nucleotide sequence shown in SEQ ID NO: 2, wherein the sense strand includes 2?-substituted nucleotides at positions 2, 3, 4 and 13 in the nucleotide sequence shown in SEQ ID NO: 1, the sense strand further includes a 2?-substituted nucleotide(s) at one or more positions selected from the group consisting of positions 12, 14, 17, 18 and 19 in the nucleotide sequence shown in SEQ ID NO: 1, wherein the position 2? of the 2?-substituted nucleotides is —R1, —OR1, —R2OR1, —OR2OR1 or —R3OR2OR1, wherein R1 represents a C1-4 alkyl group, and R2 and R3 independently represent a C1-3 alkylene group.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: February 4, 2020
    Assignee: GeneCare Research Institute Co., Ltd.
    Inventors: Kazunobu Futami, Yasuhiro Furuichi, Satoshi Kaneto
  • Patent number: 10544416
    Abstract: The invention provides a method for generating an oligonucleotide with which an exon may be skipped in a pre-mRNA and thus excluded from a produced mRNA thereof. Further provided are methods for altering the secondary structure of an mRNA to interfere with splicing processes and uses of the oligonucleotides and methods in the treatment of disease. Further provided are pharmaceutical compositions and methods and means for inducing skipping of several exons in a pre-mRNA.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: January 28, 2020
    Assignee: ACADEMISCH ZIEKENHUIS LEIDEN
    Inventor: Judith C. Van Deutekom
  • Patent number: 10543286
    Abstract: The present disclosure provides methods of treating a human having a disease or disorder that would benefit from increasing platelet counts. The method involves inhibiting the enzyme activity of biliverdin IX? reductase (BLVRB) activity or inhibiting the expression of BLVRB gene.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: January 28, 2020
    Assignee: The Research Foundation for The State University of New York
    Inventors: Wadie F. Bahou, Song Wu
  • Patent number: 10543226
    Abstract: The present disclosure provides pharmaceutical compositions comprising nucleic acids capable of targeting IGF-1R expression in M2 cells. The present disclosure also provides methods for the selective reduction of M2 cells by targeting expression of IGF-1R in these cells. The present disclosure further provides methods for treating cancer and enhancing therapeutic by targeting expression of IGF-1R in M2 cells in patients. The pharmaceutical composition of the present invention is effective when administered systemically to subjects in need thereof. The ease of administration of the pharmaceutical composition facilitates treatment and enhances patient compliance.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: January 28, 2020
    Assignee: Thomas Jefferson University
    Inventors: David W. Andrews, Douglas C. Hooper
  • Patent number: 10538767
    Abstract: Treatment of tumors, especially breast cancer or glioblastoma tumors, by silencing RAB27A and/or TRAF3IP2, compositions and methods for same.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: January 21, 2020
    Assignee: The Administrators of the Tulane Educational Fund
    Inventors: Eckhard Alt, Reza Izadpanah
  • Patent number: 10538762
    Abstract: Provided herein are compositions and methods for reducing expression of C9orf72 transcripts in cells containing expanded intronic GGGGCC regions, including those in subjects having or at risk of developing amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Provided herein are a double-stranded oligonucleotides of 13 to 22 nucleobases in length targeting a GGGGCC expanded repeat region in an intron of C9orf72, comprises (a) 3-5 central mismatches (within bases 9-14) within a target sequence comprising the expanded repeat sequence, or (h) 3-5 mismatches outside of the seed sequence (bases 2-8 within the guide strand complementary to the expanded repeat sequence).
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: January 21, 2020
    Assignee: The Board of Regents of the University of Texas System
    Inventors: David Corey, Jiaxin Hu
  • Patent number: 10533171
    Abstract: The invention provides an oligonucleotide comprising an inosine, and/or a nucleotide containing a base able to form a wobble base pair or a functional equivalent thereof, wherein the oligonucleotide, or a functional equivalent thereof, comprises a sequence which is complementary to at least part of a dystrophin pre-m RNA exon or at least part of a non-exon region of a dystrophin pre-m RNA said part being a contiguous stretch comprising at least 8 nucleotides. The invention further provides the use of said oligonucleotide for preventing or treating DMD or BMD.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: January 14, 2020
    Assignee: BioMarin Technologies B.V.
    Inventors: Judith Christina Theodora Van Deutekom, Josephus Johannes De Kimpe, Gerard Johannes Platenburg
  • Patent number: 10525077
    Abstract: The present invention provides an oligodeoxy nucleotide for preparing drugs for inhibiting tumor growth and an application thereof. The core sequence of the oligodeoxy nucleotide is TTYSGGAAWT, wherein Y is C or T; S is C or G; and W is A or T. The oligodeoxy nucleotide above further comprises an antisense strand and a modified type thereof. The oligodeoxy nucleotide according to the present invention plays a role of inhibiting the tumor growth in vitro and vivo, and is expected to be used for preparing drugs for inhibiting tumor growth, with high specificity and high inhibition ratio.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: January 7, 2020
    Assignees: JIANGSU KEYGEN BIOTECH CORP., LTD, NANJING NEW INDUSTRY INVESTMENT GROUP CO., LTD
    Inventors: Xuegen Wang, Qing Ye, Yijun Sun